Immunic, Inc. Common Stock
Here’s whether Immunic, Inc. Common Stock (IMUX) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bullish.
Positives: trading above the 200-day MA (long-term uptrend intact); 50-day MA is rising (+10.42% over 10 days); RSI 44 — healthy momentum range; 3-month momentum positive (+61.8%). Concerns: below the 50-day MA (medium-term momentum negative). Currently 33.8% off its 52-week high. Score: +4/7.
IMUX is holding above its long-term 200-day MA ($0.86) but has slipped below the 50-day MA ($1.07), pointing to short-term weakness in an otherwise intact trend. An RSI of 43.7 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of +6.1% compares to +35.1% for SPY (trailed the market by 29.0%). The current 33.8% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.